Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.

Source: Cephalalgia 2023 Jan; 43(1). doi: 10.1177/03331024221128250Authors: Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M, Trugman JM

Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of atogepant in participants who completed the phase 3 ADVANCE trial (NCT03777059).

Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36620892?dopt=Abstract